1. The first biosimilar of Rituxan, called Truxima, was approved for the treatment of adult patients with non-Hodgkin lymphoma.
2. Xospata, which are tablets, treat adult patients who have acute myeloid leukemia with a certain genetic mutation or who were in remission and relapsed.
3. The FDA approved Firdapse, the first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder that affects the connection between nerves, causing weakness in affected patients.
4. Vitrakvi is an oncology drug that treats cancers that have a specific genetic feature, also known as a biomarker. It does not target a specific type of tumor like many cancer treatments.
5. ATCPen, a single-dose prefilled autoinjector of tocilizumab, for the treatment of moderate to severe rheumatoid arthritis.
More articles on supply chain:
What’s next? 5 predictions for the healthcare supply chain in 2019
Cleveland Clinic leads list of 25 top healthcare supply chains for 2018
Sales reps may get the boot from hospital ORs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
